There are currently 187 clinical trials in Tulsa, Oklahoma looking for participants to engage in research studies. Trials are conducted at various facilities, including Oklahoma Cancer Specialists and Research Institute-Tulsa, Natalie Warren Bryant Cancer Center at St. Francis Hospital, GSK Investigational Site and Natalie Warren Bryant Cancer Center at Saint Francis. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
NCT05857930
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
07/21/2025
Locations: Vital Prospects Clinical Research Institute, PC, Tulsa, Oklahoma
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
Register for Updates
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Essential Medical Research, Tulsa, Oklahoma
Conditions: Psoriatic Arthritis, Overweight or Obesity
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
NCT06899217
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Partic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Options Health Research, Tulsa, Oklahoma
Conditions: Idiopathic Gastroparesis
Register for Updates
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934
Recruiting
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Tulsa, Oklahoma
Conditions: Eosinophilic Granulomatosis With Polyangiitis
Register for Updates
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Ascension St. John - Jane Phillips Medical Center, Tulsa, Oklahoma
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Register for Updates
Amplification of Positivity for Alcohol Use
NCT06030154
Recruiting
The proposed study consists of two phases. During Phase 1, the investigators will recruit a small sample of participants to complete a psychosocial intervention termed Amplification of Positivity (AMP) for individuals experiencing comorbid depression or anxiety disorders and alcohol use disorder (AMP-A). These participants will be asked to provide both qualitative and quantitative input about the AMP-A intervention. Based on their input and clinician input, the AMP-A manual will be modified for... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/15/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Alcohol Use Disorder, Anxiety, Depression
Register for Updates
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
NCT06454240
Recruiting
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung funct... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/15/2025
Locations: Essential Medical Research- Site Number : 8400020, Tulsa, Oklahoma
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Local Institution - 001-584, Tulsa, Oklahoma
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/14/2025
Locations: Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686
Recruiting
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma
Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Register for Updates
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06289673
Recruiting
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropri... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
07/14/2025
Locations: Saint Francis Children's Hospital, Tulsa, Oklahoma
Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06390319
Recruiting
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end o... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
07/11/2025
Locations: Saint Francis Children's Hospital, Tulsa, Oklahoma
Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates